generic glp-1 drugs Diabetes patients now have access to first medication: ‘More accessible and affordable’ FDA Approves Hikma's Generic Version
Description
4 Reddit Questions About GLP-1s, Answered by Obesity Experts People frequently turn to Reddit to ask questions and share advice about taking glucagon-like peptide-1 (GLP-1) medication to manage obesity

DPP-4 inhibitors are small molecular-weight drugs that inhibit 90% of DPP-4 activity and are orally administered on a once-daily (OD) basis [vildagliptin twice daily (BID)] 11 , 12

A patient in the 24% federal tax bracket who spends $1,788 annually on semaglutide injection (starting at $149/month) avoids approximately $429 in combined federal and FICA taxeseffectively lowering the actual cost of treatment

Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 119.00 per year only 9.92 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

63 Albiglutide was approved for marketing in the European Union in March 2014 and in the United States in April 2014
